Iván Angulo-Herrera Email and Phone Number

Team leader in the pharmacology and preclinical teamFacilitate cross functional collaboration with project leaders to deliver project milestonesSearch for new collaborations and opportunities to expand Healx pipeline

Analyze and filter results from Healx' predictive methods and establish a pharmacological rationale for potential drug repurposing candidates.Lead the selection of drug candidate molecules based on deep knowledge of disease pathways, mechanisms and drug propertiesGuide their translation through preclinical stages, providing in vitro / in vivo study design inputProvide pharmacology input for new developments in collaboration with bioinformaticians and software engineers developing… Show more Analyze and filter results from Healx' predictive methods and establish a pharmacological rationale for potential drug repurposing candidates.Lead the selection of drug candidate molecules based on deep knowledge of disease pathways, mechanisms and drug propertiesGuide their translation through preclinical stages, providing in vitro / in vivo study design inputProvide pharmacology input for new developments in collaboration with bioinformaticians and software engineers developing algorithmic methods and toolGenerate and maintain long term relationships with Healx partners Show less

I am part of integrated drug discovery team. My work focus on identification and validation of therapeutic targets and biomarkers for CNS diseases by combining human primary cellular assays, high-content screening (HCS) and study of the mechanism of action of small molecules.

R&D of antibacterial therapeutics, using synthetic biology we redesign microorganisms which incorporate novel antibacterial features.

We studied PID (primary immunodeficiency) patients in collaboration with clinical scientists. We used whole exome sequencing to search for causative mutations, followed by detailed functional molecular analyses of the affected cellular pathways.We discovered a novel PID called Activated PI3K-Delta Syndrome (APDS), which is caused by a dominant gain-of-function mutation in the Phosphoinositide 3-kinase δ Gene. APDS patients have antibody deficiency, suffer recurrent respiratory infections and… Show more We studied PID (primary immunodeficiency) patients in collaboration with clinical scientists. We used whole exome sequencing to search for causative mutations, followed by detailed functional molecular analyses of the affected cellular pathways.We discovered a novel PID called Activated PI3K-Delta Syndrome (APDS), which is caused by a dominant gain-of-function mutation in the Phosphoinositide 3-kinase δ Gene. APDS patients have antibody deficiency, suffer recurrent respiratory infections and rapidly develop airway damage. Our study suggests that selective PI3Kδ inhibitors may provide a novel specific and efficient treatment approach for APDS patients. Show less

I studied the role of the NS5A protein of the hepatitis C virus (HCV) in viral RNA replication, by direct mutagenesis of we established the connection between the RNA binding capacity of NS5A and viral replication. I also was in charge of a project to discover cellular factors that are relevant for the HCV replication. Using the siRNA technology we identified and validated several host factors relevant for the HCV replication.

As part of the structural biology team I was in charge of the designing, cloning, expression, purification and crystallization of proteins. I also developed a new method of expression and purification of recombinant proteins with an affinity tag, this methodology enhance the solubility and reduce to just one step the purification protocol.

I developed new diagnostic methods and new generation vaccines for viruses relevant for animal health, such as classical swine fever virus (CSFV), foot and mouth disease virus (FMDV) and rabbit hemorrhagic disease virus (RHDV). I obtained strain specific monoclonal antibodies against CSFV to improve a differential diagnostic ELISA during this time. My Ph.D., thesis research consisted of determining the structural requirements for the production of recombinant viral like particles (VLPs) of RHDV… Show more I developed new diagnostic methods and new generation vaccines for viruses relevant for animal health, such as classical swine fever virus (CSFV), foot and mouth disease virus (FMDV) and rabbit hemorrhagic disease virus (RHDV). I obtained strain specific monoclonal antibodies against CSFV to improve a differential diagnostic ELISA during this time. My Ph.D., thesis research consisted of determining the structural requirements for the production of recombinant viral like particles (VLPs) of RHDV and the use of these VLPs as a platform for insertion of immunogenic epitopes of FMDV as a recombinant vaccine. We discover the aminoacid residues that determine the cell tropism of the Feline Calicivirus, which is an interesting finding and a contribution to the understanding of the biology of Caliviruses Show less